Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Sep 23, 2026 5.07 Submission of matters to a vote of security holders; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 14, 2026 8.01 Other events
10-K Jun 30, 2026 1: 3 added · 3 removed · 37 modified
1A: 28 added · 2 removed · 31 modified
7: 16 added · 18 removed · 50 modified
8-K Aug 12, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 23, 2026 1.01 Entry into a material definitive agreement; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Jun 25, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026 P1I2: 11 modified
P2I1A: no material changes, the filing says
8-K May 6, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 9, 2026 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Dec 31, 2025
8-K Feb 4, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 5.07 Submission of matters to a vote of security holders; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Jun 30, 2025
10-Q Mar 31, 2025

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.